Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Opus Genetics has completed patient enrollment in its registrational Phase 3 trial of OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease. The trial design aligns with FDA Rare Disease Evidence Principles, aiming for a Biologics License Application submission based on six-month efficacy data expected by the end …